<DOC>
	<DOCNO>NCT00741871</DOCNO>
	<brief_summary>This Phase 1 dose escalation study determine maximum tolerate dose dose limit toxicity SB1518 give alone daily mouth subject advance lymphoid malignancy .</brief_summary>
	<brief_title>A Phase 1 Study SB1518 Treatment Advanced Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Subjects histologically document diagnosis lymphoid malignancy define World Health Organization ( WHO ) classification scheme except list Exclusion Criteria Subject must receive least 2 prior regimen lymphoid malignancy , one anthracyclinecontaining combination regimen show disease relapse respond prior regimen Subjects classic HL diffuse large B cell lymphoma must fail , refuse ineligible receive stem cell transplant Subjects must measurable lesion ( least one target lesion measure 2cm diameter ) computerize tomography ( CT ) scan Eastern Cooperative Oncology Group ( ECOG ) performance status 02 All men reproductive potential woman childbearing potential must agree practice effective contraception entire study period one month last study treatment unless documentation infertility exist . Additionally , woman childbearing potential must negative pregnancy test within 14 day prior first dose study drug Able understand willing sign inform consent form PostTransplant Lymphoproliferative Disease ( PTLD ) , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia , multiple myeloma , HIVassociated lymphoma History active Central Nervous System ( CNS ) malignancy Have undergo allogeneic stem cell transplant treat immunosuppressing agent within past 6 month Active Graftversushost disease ( GVHD ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement judge treat physician . Subjects receive antibiotic infection control may include study Concurrent malignancy , except subject early stage squamous cell carcinoma skin , basal cell carcinoma skin , cervical intraepithelial neoplasia eligible study Known HIVpositive ( subject increase risk lethal infection treat potentially marrowsuppressive therapy ) Known active Hepatitis A , B C Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lymphoid malignancy</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Diffuse large B cell lymphoma</keyword>
</DOC>